PDCD1 and neoplasm: Importantly, treatment with 200 μg of anti‐RANKL/PD‐1 BsAb significantly improved the tumor rejection rate (12/15 mice) vs. combination of anti‐RANKL plus anti‐PD‐1 antibodies (3/15; Fisher's exact test **P = 0.0028).